JP2020500168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500168A5 JP2020500168A5 JP2019521720A JP2019521720A JP2020500168A5 JP 2020500168 A5 JP2020500168 A5 JP 2020500168A5 JP 2019521720 A JP2019521720 A JP 2019521720A JP 2019521720 A JP2019521720 A JP 2019521720A JP 2020500168 A5 JP2020500168 A5 JP 2020500168A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- fraction
- excipient
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022165319A JP2023011659A (ja) | 2016-10-24 | 2022-10-14 | 分散性組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621036404 | 2016-10-24 | ||
| IN201621036404 | 2016-10-24 | ||
| PCT/EP2017/077030 WO2018077815A1 (en) | 2016-10-24 | 2017-10-23 | Dispersible compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022165319A Division JP2023011659A (ja) | 2016-10-24 | 2022-10-14 | 分散性組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500168A JP2020500168A (ja) | 2020-01-09 |
| JP2020500168A5 true JP2020500168A5 (enExample) | 2020-12-10 |
| JP7197474B2 JP7197474B2 (ja) | 2022-12-27 |
Family
ID=60262899
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521720A Active JP7197474B2 (ja) | 2016-10-24 | 2017-10-23 | 分散性組成物 |
| JP2022165319A Withdrawn JP2023011659A (ja) | 2016-10-24 | 2022-10-14 | 分散性組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022165319A Withdrawn JP2023011659A (ja) | 2016-10-24 | 2022-10-14 | 分散性組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11065198B2 (enExample) |
| EP (2) | EP3528791B1 (enExample) |
| JP (2) | JP7197474B2 (enExample) |
| KR (2) | KR102861006B1 (enExample) |
| CN (1) | CN110191704A (enExample) |
| CA (1) | CA3039562A1 (enExample) |
| DK (1) | DK3528791T3 (enExample) |
| ES (1) | ES2970870T3 (enExample) |
| FI (1) | FI3528791T3 (enExample) |
| HR (1) | HRP20240118T1 (enExample) |
| HU (1) | HUE064823T2 (enExample) |
| LT (1) | LT3528791T (enExample) |
| MA (1) | MA46563B1 (enExample) |
| MX (1) | MX2019004767A (enExample) |
| PL (1) | PL3528791T3 (enExample) |
| PT (1) | PT3528791T (enExample) |
| RS (1) | RS65159B1 (enExample) |
| SI (1) | SI3528791T1 (enExample) |
| SM (1) | SMT202400060T1 (enExample) |
| TW (1) | TWI821163B (enExample) |
| WO (1) | WO2018077815A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021026916A2 (pt) * | 2019-07-03 | 2022-05-10 | Janssen Sciences Ireland Unlimited Co | Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina |
| CA3152105A1 (en) | 2019-11-29 | 2021-06-03 | Wai Yip Thomas Lee | Composition including rilpivirine and use thereof for treating tumors or cancer |
| WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
| CN114392241B (zh) * | 2022-01-10 | 2023-07-25 | 安徽贝克生物制药有限公司 | 一种利匹韦林片及其制备方法 |
| GB202211231D0 (en) * | 2022-08-02 | 2022-09-14 | Glaxosmithkline Ip No 2 Ltd | Novel formulation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0181966A1 (en) * | 1984-11-13 | 1986-05-28 | Gist-Brocades N.V. | Compression-coated dispersible tablets |
| GB9109862D0 (en) * | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| PL208533B1 (pl) | 2002-08-09 | 2011-05-31 | Janssen Pharmaceutica Nv | Sposób otrzymywania 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu oraz sposób otrzymywania związku pośredniego |
| WO2006024668A1 (en) | 2004-09-02 | 2006-03-09 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile |
| UA92469C2 (en) * | 2004-09-02 | 2010-11-10 | Янссен Фармацевтика Н.В. | Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile |
| PT1632232E (pt) | 2004-09-02 | 2011-08-02 | Janssen Pharmaceutica Nv | Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo |
| UA97641C2 (xx) | 2006-06-23 | 2012-03-12 | Тиботек Фармасьютикелз Лтд. | Водна суспензія 4-$$4-$$4-(2-ціаноетеніл)-2,6-диметилфеніл]аміно]-2-піримідиніл]аміно]бензонітрилу (tmc278)$водная суспензия 4-$$4-$$4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила (тмс278) |
| EP3102188A4 (en) | 2014-02-05 | 2017-07-12 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
| WO2015136294A1 (en) * | 2014-03-13 | 2015-09-17 | Cipla Limited | Pharmaceutical composittion comprising rilpivirine |
| WO2015176008A1 (en) * | 2014-05-16 | 2015-11-19 | Vivus, Inc. | Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use |
-
2017
- 2017-10-23 HU HUE17794275A patent/HUE064823T2/hu unknown
- 2017-10-23 CA CA3039562A patent/CA3039562A1/en active Pending
- 2017-10-23 PT PT177942752T patent/PT3528791T/pt unknown
- 2017-10-23 SM SM20240060T patent/SMT202400060T1/it unknown
- 2017-10-23 CN CN201780065671.8A patent/CN110191704A/zh active Pending
- 2017-10-23 SI SI201731486T patent/SI3528791T1/sl unknown
- 2017-10-23 EP EP17794275.2A patent/EP3528791B1/en active Active
- 2017-10-23 DK DK17794275.2T patent/DK3528791T3/da active
- 2017-10-23 EP EP23169649.3A patent/EP4248947A3/en active Pending
- 2017-10-23 HR HRP20240118TT patent/HRP20240118T1/hr unknown
- 2017-10-23 ES ES17794275T patent/ES2970870T3/es active Active
- 2017-10-23 US US16/344,143 patent/US11065198B2/en active Active
- 2017-10-23 MA MA46563A patent/MA46563B1/fr unknown
- 2017-10-23 FI FIEP17794275.2T patent/FI3528791T3/fi active
- 2017-10-23 MX MX2019004767A patent/MX2019004767A/es unknown
- 2017-10-23 KR KR1020247001197A patent/KR102861006B1/ko active Active
- 2017-10-23 RS RS20240158A patent/RS65159B1/sr unknown
- 2017-10-23 PL PL17794275.2T patent/PL3528791T3/pl unknown
- 2017-10-23 JP JP2019521720A patent/JP7197474B2/ja active Active
- 2017-10-23 WO PCT/EP2017/077030 patent/WO2018077815A1/en not_active Ceased
- 2017-10-23 KR KR1020197014202A patent/KR20190073450A/ko not_active Ceased
- 2017-10-23 LT LTEPPCT/EP2017/077030T patent/LT3528791T/lt unknown
- 2017-10-24 TW TW106136552A patent/TWI821163B/zh active
-
2021
- 2021-06-15 US US17/347,929 patent/US20220008333A1/en not_active Abandoned
-
2022
- 2022-10-14 JP JP2022165319A patent/JP2023011659A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500168A5 (enExample) | ||
| JP6875407B2 (ja) | Ｊａｋキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物 | |
| US8309126B2 (en) | Dispersible bosentan tablet | |
| FI3265084T3 (fi) | Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita | |
| TWI583384B (zh) | 包含４－胺基－５－氟－３－［６－（４－甲基哌嗪－１－基）－１ｈ－苯并咪唑－２－基］－１ｈ－喹啉－２－酮乳酸鹽單水合物之醫藥組合物 | |
| JP2017528503A5 (enExample) | ||
| JP2006516570A5 (enExample) | ||
| JP2014533733A5 (enExample) | ||
| JP2015511621A5 (enExample) | ||
| RU2019122414A (ru) | Антивирусные алифатические сложноэфирные пролекарства тенофовира | |
| NZ627963A (en) | Dry powder pharmaceutical formulations for inhalation of a compound that inhibits pi3 kinase | |
| US20150104511A1 (en) | Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine | |
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| JP2019536812A5 (enExample) | ||
| FI3528791T3 (fi) | Dispergoituvia koostumuksia | |
| JP2010520891A (ja) | ネビラピンの徐放性製剤 | |
| HRP20251043T1 (hr) | Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća | |
| FI3389638T3 (fi) | Pimobendaania käsittävä lääkekoostumus | |
| WO2021091498A1 (en) | Pharmaceutical compositions comprising tenofovir and emtricitabine | |
| JP2018184382A (ja) | エゼチミブ含有錠剤およびその製法 | |
| ZA202200331B (en) | Naltrexone formulation | |
| JP2018184381A (ja) | エゼチミブ含有錠剤およびその製法 | |
| WO2013154512A1 (en) | Pharmaceutical formulations comprising dexibuprofen | |
| JP2010516712A5 (enExample) | ||
| ES2875405T3 (es) | Composición farmacéutica que comprende darunavir y método para su preparación |